

Form PTO-1449
(Rev. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO:
102194-6APPLICATION NO:
09/491,896

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT:
Matthew J. DuringFILING DATE:
January 24, 2000GROUP ART UNIT:
1643 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*	
BBB	AA	5	5	3	2	2	6	5	07/96	Gijbels et al.	514	419	—	—
BBB	AB	5	8	5	1	9	9	6	12/98	Kline	514	12	—	—
BBB	AC	5	7	5	3	6	2	4	05/98	McMichael et al.	514	12	—	—
BBB	AD	5	8	2	7	8	1	9	10/98	Yatvin et al.	514	2	—	—

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
BBB	BA	2	0	8	7	7	3	8	07/94	Canada	—	—	—	—

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

BBB	CA	Charles, V. et al., "Atrophy of Cholinergic Basal Forebrain Neurons Following Excitotoxic Cortical Lesions is Reversed by Intravenous Administration of an NGF Conjugate," <i>Brain Research</i> , vol. 728, 193-203 (1996);												
BBB	CB	During, M. et al., "Peroral Gene Therapy of Lactose Intolerance Using an Adeno-Associated Virus Vector," <i>Nature Medicine</i> , vol. 4, no. 10, 1131-5 (Oct. 1998);												
BBB	CC	Lobell, A. et al., "Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis," <i>Journal of Experimental Medicine</i> , vol. 187, no. 9, 1543-8 (May 4, 1998);												
BBB	CD	Schehr, R., "New Treatments for Acute Stroke," <i>Nature Biotechnology</i> , vol. 14, 1549-54 (November 14, 1996);												
BBB	CE	Schenk, D. et al., "Immunization with Amyloid- β Attenuates Alzheimer-disease-like Pathology in the PDAPP Mouse," <i>Nature</i> , vol. 400, 173-7 (1999);												
BBB	CF	Stanton, P.K. et al., "A Monoclonal Antibody which Mimicks Glycine Actions on N-Methyl-D-Aspartate Receptors has Complex Effects on Channel Activation and Neuronal Sensitivity to Hypoxia," <i>Society for Neuroscience Abstracts</i> , vol. 16, no. 1, pg. 88 (January 1, 1990);												
Examiner		Date Considered: <u>Bridget C. Bunner 2/2/01</u>												
		*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.												

Form PTO-1449
(Rev. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO:
102194-6APPLICATION NO:
09/491,896

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT:
Matthew J. DuringFILING DATE:
January 24, 2000GROUP ART UNIT:
1643 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

BEB	CG	Sun, F. and Faden, A., "Pretreatment with Antisense Oligodeoxynucleotides Directed Against the NMDA-R1
		Receptor Enhances Survival and Behavioral Recovery Following Traumatic Brain Injury in Rats," <i>Brain Research</i> ,
		vol. 693, 163-8 (1995);
BEB	CH	Wahlestedt, C. et al., "Antisense Oligodeoxynucleotides to NMDA-R1 Receptor Channel Protect Cortical Neurons
		from Excitotoxicity and Reduce Focal Ischaemic Infarctions," <i>Nature</i> , vol. 363, 260-3 (May 20, 1993).
Examiner		Date Considered: <u>Bridget E. Bunner</u> <u>2/2/01</u>
		*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant. #879589v1 < imange > -ids 1449.wpd